| Ytd | -6.08% | |
| 1y | -49.23% |
| Open | 0.94 | Prev Close | 0.94 | Low | 0.93 | High | 0.94 | Mkt Cap | 57.43M |
| Vol | 22.62K | Avg Vol | 714.52K | EPS | -0.96 | P/E | -0.98 | Forward P/E | -2.33 |
| Beta | 1.04 | Short Ratio | 9.02 | Inst. Own | 86.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.00 | 200-d Avg | 1.18 | 1yr Est | 12.14 |
TCRX News
WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeu
SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Cellares, the first Integrated Develo
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Z
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks C
Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of He
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercia
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica
TScan Therapeutics, Inc. (NASDAQ: TCRX - Get Free Report) has received an average rating of "Hold" f
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0. 50; p=0. 23) and overa
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia eliminat
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks C
Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 m
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 D
On Friday, 1043 companies hit new 52-week lows.